Effect of Erenumab on Patient-Reported Outcomes in Episodic Migraine in Asia, the Middle East, and Latin America: Results From the EMPOwER Study
Document Type
Article
Publication Date
2-2-2026
Abstract
Background and Objectives – Migraine is a significant disabling neurologic headache disorder globally. Evaluating patient-related outcomes (PROs) is necessary to assess the impact of therapeutic interventions in preventive therapy. An exploratory analysis of data from the EMPOwER study examined the effect of erenumab on PROs in patients with episodic migraine (EM) in regions underrepresented in the pivotal Phase 3 trials of erenumab, specifically Asia, the Middle East, and Latin America.Methods – Patients (N = 900) were randomized (2:3:3) to receive monthly subcutaneous injections of erenumab 140 mg, erenumab 70 mg, or placebo. Adjusted mean changes from baseline in the Headache Impact Test (HIT-6), Migraine Physical Function Impact Diary (MPFID), modified Migraine Disability Assessment (mMIDAS), and EuroQoL 5-dimension 5-level scale (EQ-5D-5L) scores were assessed during the double-blind treatment phase of 3 months.Results – A statistically significant reduction from baseline in the HIT-6 total score was observed for erenumab 140 mg (−9.34, p < 0.001) and 70 mg (−8.39, p = 0.004) vs placebo (−6.62) at Month 3. Improvement in MPFID scores was also greater in the erenumab groups vs the placebo group (Everyday Activity: 140 mg, −5.61 [p = 0.002]; 70 mg, −4.94 [p = 0.011]; placebo, −3.19; Physical Impairment: 140 mg, −4.27 [p = 0.014]; 70 mg, −3.95 [p = 0.021]; placebo, −2.31) at Month 3. Similar findings were observed for mMIDAS scores (140 mg −8.99 [p < 0.001], 70 mg −8.11 [p = 0.011] vs placebo [−6.59]) and the EQ-5D-5L quality-of-life visual analog scale scores (140 mg 8.13 [p = 0.017], 70 mg 7.08 [p = 0.088] vs placebo [5.22]), although no meaningful between-group difference was noted for index values.Discussion – Erenumab showed favorable effects on PROs when compared with placebo in patients with EM. These results enhance the evidence for erenumab as an effective preventive therapy for patients with EM.Trial Registration Information – Clinicaltrials.gov/study/NCT03333109.
Keywords
adult; Article; Asia; controlled study; double blind procedure; drug effect; episodic migraine; European Quality of Life 5 Dimensions questionnaire; female; human; major clinical study; male; MIDAS (migraine); Middle East; patient-reported outcome; physical disease; quality of life; randomized controlled trial; scoring system; South and Central America; visual analog scale
Publication Title
Neurology Clinical Practice
ISSN
2163-0402
DOI
10.1212/CPJ.0000000000200565
Recommended Citation
Wang, Shuu Jiun; Roxas, Artemio A.; Saravia, Bibiana; Kim, Byung Kun; Chowdhury, Debashish; Riachi, Naji J.; Tai, Mei Ling Sharon; Tanprawate, Surat; Tran, Tai Ngoc; Zhao, Yi Jing; Su, Wendy; Wen, Shihua; Mondal, Subhayan; Ecochard, Laurent; and Arkuszewski, Michal, "Effect of Erenumab on Patient-Reported Outcomes in Episodic Migraine in Asia, the Middle East, and Latin America: Results From the EMPOwER Study" (2026). Research Publications (2026 to 2030). 1263.
https://knova.um.edu.my/research_publications_2026_2030/1263
Volume
16
Issue
2
First Page
e200565
Publisher
Lippincott Williams and Wilkins